DM 618
Alternative Names: DM-618Latest Information Update: 28 Apr 2026
At a glance
- Originator D2M Biotherapeutics
- Class Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 12 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders